BRIEF published on 05/11/2026 at 08:05, 3 hours 24 minutes ago Pentixapharm soumet une demande d'autorisation d'essai clinique (IND) à la FDA pour l'étude de phase 3 PANDA. Diagnostic De Précision Pentixapharm Phase 3 PANDA Soumission D'autorisation De Mise Sur Le Marché (IND) À La FDA Imagerie Cardiovasculaire
BRIEF published on 05/11/2026 at 08:05, 3 hours 24 minutes ago Pentixapharm Submits IND to FDA for Phase 3 PANDA Study Pentixapharm Precision Diagnostics FDA IND Submission Phase 3 PANDA Cardiovascular Imaging
PRESS RELEASE published on 05/11/2026 at 08:00, 3 hours 29 minutes ago Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic Pentixapharm submits IND to FDA for Phase 3 PANDA study of CXCR4-targeted cardiovascular diagnostic, aiming at precision diagnostics in primary aldosteronism Pentixapharm IND Submission Phase 3 PANDA Study CXCR4-targeted Cardiovascular Diagnostic
BRIEF published on 05/07/2026 at 08:05, 4 days 3 hours ago Point sur le développement financier et clinique de Pentixapharm au premier trimestre 2026 Résultats Financiers Développement Clinique Gestion Des Coûts Produits Radiopharmaceutiques Commentaires Réglementaires
BRIEF published on 05/07/2026 at 08:05, 4 days 3 hours ago Pentixapharm Q1 2026 Financial and Clinical Development Update Financial Results Clinical Development Radiopharmaceuticals Cost Management Regulatory Feedback
PRESS RELEASE published on 05/07/2026 at 08:00, 4 days 3 hours ago Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum Pentixapharm Holding AG reports Q1 2026 financial results, highlights progress in clinical and regulatory activities, and provides full-year financial guidance Financial Results Regulatory Pentixapharm Q1 2026 Clinical
BRIEF published on 03/31/2026 at 08:05, 1 month 11 days ago Pentixapharm Holding AG Appoints Erik Merten to Executive Board Executive Board Radiopharmaceuticals Pentixapharm Erik Merten PANDA Program
BRIEF published on 03/31/2026 at 08:05, 1 month 11 days ago Pentixapharm Holding AG nomme Erik Merten au conseil d'administration Conseil D'administration Produits Radiopharmaceutiques Pentixapharm Erik Merten Programme PANDA
PRESS RELEASE published on 03/31/2026 at 08:00, 1 month 11 days ago Pentixapharm Holding AG Appoints Erik Merten to the Executive Board Pentixapharm Holding AG appoints Erik Merten as Chief Technology Officer (CTO) to enhance radiopharmaceutical development and manufacturing capabilities, supporting Phase 3 PANDA program and future commercialization Executive Board Radiopharmaceuticals Pentixapharm Holding AG Erik Merten Phase 3 PANDA Program
BRIEF published on 03/19/2026 at 10:19, 1 month 23 days ago Pentixapharm Holding AG to Reveal 2025 Financial Results Conference Call Clinical Trials Pentixapharm Radiotherapeutics 2025 Financial Results
Published on 05/11/2026 at 09:05, 2 hours 24 minutes ago Ameriwest Outlines Multiple Additional Breccia Pipe-Style Targets at Bornite from Historical Soil Sampling and Mapping
Published on 05/11/2026 at 08:05, 3 hours 24 minutes ago Tocvan Accelerates Gran Pilar: 5,000+ Meters Drilled to Date, Historic Workings Discovered on South Block, Pilot Progresses
Published on 05/09/2026 at 01:30, 2 days 9 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/11/2026 at 11:17, 12 minutes ago Aroundtown SA: Release of a capital market information
Published on 05/11/2026 at 11:10, 18 minutes ago Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Buy
Published on 05/11/2026 at 11:09, 19 minutes ago Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for Entry into the Compounding Market
Published on 05/11/2026 at 11:00, 29 minutes ago Shelly Group: Invitation to Earnings Webcast/Call on 12 May 2026 on Unaudited 3M 2026 Results
Published on 05/11/2026 at 10:48, 41 minutes ago GUILLEMOT CORPORATION | Weekly report share buyback from May 4 to May 8 2026
Published on 05/11/2026 at 10:48, 41 minutes ago GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 4 au 8 mai 2026
Published on 05/11/2026 at 09:16, 2 hours 13 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 28 avril 2026
Published on 05/07/2026 at 19:15, 3 days 16 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 16 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
